Shionogi Acquires Tetra Therapeutics, Rights to Fragile X Treatment
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improved cognitive function in men with fragile X syndrome.| Fragile X News Today
Tetra Therapeutics has amended the protocols of two ongoing clinical trials testing zatolmilast to improve access for fragile X patients.| Fragile X News Today
